Birchview Capital, LP 2seventy Bio, Inc. Transaction History
Birchview Capital, LP
- $111 Million
- Q1 2025
A detailed history of Birchview Capital, LP transactions in 2seventy Bio, Inc. stock. As of the latest transaction made, Birchview Capital, LP holds 15,500 shares of TSVT stock, worth $77,500. This represents 0.07% of its overall portfolio holdings.
Number of Shares
15,500
Previous 15,833
2.1%
Holding current value
$77,500
Previous $46,000
65.22%
% of portfolio
0.07%
Previous 0.04%
Shares
11 transactions
Others Institutions Holding TSVT
# of Institutions
152Shares Held
46.7MCall Options Held
116KPut Options Held
7.5K-
Goldman Sachs Group Inc New York, NY4.68MShares$23.4 Million0.0% of portfolio
-
Beryl Capital Management LLC Redondo Beach, CA4.25MShares$21.3 Million8.75% of portfolio
-
Black Rock Inc. New York, NY3.66MShares$18.3 Million0.0% of portfolio
-
Morgan Stanley New York, NY2.97MShares$14.8 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.82MShares$14.1 Million0.0% of portfolio
About 2seventy bio, Inc.
- Ticker TSVT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 37,873,600
- Market Cap $189M
- Description
- 2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. Its products pipeline includes idecabtagene vicleucel; ide-cel or Abecma and bb21217; and CAR-T cell product candidates for the treatment of multiple myeloma. 2seventy bio, Inc. has a col...